Individual Women, Individual HRT


A combined portfolio of HRT treatment options

MyWay HRT Range
Overview and
Stock Availability

With multiple products for mono, sequential and continuous
combined needs,
view the MyWay HRT range AND availability below

Stock Status Key

In Stock

Current Stock Constraint

MONO FORMULATION OPTIONS (17ß ESTRADIOL)
Elleste logo Elleste™ Solo
Doses:
  • 1mg estradiol
  • 2mg estradiol
Elleste Solo™ MX
Doses:
  • 40mcg transdermal estradiol
  • 80mcg transdermal estradiol
Zumenon logo Zumenon®
Doses:
  • 1mg estradiol
  • 2mg estradiol
SEQUENTIAL COMBINED FORMULATION OPTIONS
(17ß ESTRADIOL + PROGESTIN)
Elleste logo Elleste Duet™
Doses:
  • 1mg estradiol + 1mg norethisterone acetate
  • 2mg estradiol + 1mg norethisterone acetate
Femoston logo Femoston®
Doses:
  • 1mg estradiol + 10mg dydrogesterone
  • 2mg estradiol + 10mg dydrogesterone
CONTINUOUS COMBINED FORMULATION OPTIONS
(17ß ESTRADIOL + PROGESTIN)
Elleste logo Elleste Duet™ Conti
Doses:
  • 2mg estradiol + 1mg norethisterone
Femoston logo Femoston® conti
Doses:
  • 0.5mg estradiol + 2.5mg
    dydrogesterone
  • 1mg estradiol + 5mg
    dydrogesterone
Elleste logo Femoston logo Femoston conti logo Zumenon logo
Forulaton options

Mono Formulations
17ß Estradiol only

Elleste™ Solo
Doses:
  • 1mg estradiol
  • 2mg estradiol
Elleste Solo™ MX
Doses:
  • 40mcg transdermal
    estradiol
  • 80mcg transdermal
    estradiol
Zumenon®
Doses:
  • 1mg estradiol
  • 2mg estradiol

Sequential Combined
Formulations

17ß Estradiol+progestin

Elleste Duet™
Doses:
  • 1mg estradiol + 1mg norethisterone acetate
  • 2mg estradiol + 1mg norethisterone acetate
Femoston®
Doses:
  • 1mg estradiol + 10mg dydrogesterone
  • 2mg estradiol + 10mg dydrogesterone

Continuous Combined
Formulations

17ß Estradiol + progestin

Elleste Duet™ Conti
Doses:
  • 2mg estradiol + 1mg norethisterone
Femoston® conti
Doses:
  • 0.5mg estradiol + 2.5mg
    dydrogesterone
  • 1mg estradiol + 5mg
    dydrogesterone

Considerations

Why 17ß estradiol?

Non-equine
Body-identical 17ß estradiol

Why Dydrogesterone?

  • The Femoston® range of products contain both 17ß estrodiol and
    dydrogesterone
  • The Femoston® range offers both sequential and continuous combined options
  • Dydrogesterone’s molecular structure and shape makes it a highly selective
    progestin, binding almost exclusively to the progestogen receptors1
  • In comparison to progesterone, dydrogesterone has increased bioavailability and has some progestogenic metabolites meaning that a dose of 10-20 times lower is adequate for endometrial proliferation1

Progestogenic Side Effect Profiles1

Progestogen
Progestogenic
Oestrogenic
Androgenic
Anti-androgenic
Glucocorticoid
Anti-
mineralo-corticoid
Progesterone + ± + +
Dydrogesterone + ± ±
Drospirenone + + +
MPA* + ± +
Norethisterone + + +
Levonorgestrel + +

+ Effective; ± Weakly effective; – Not effective
*MPA: medroxyprogesterone acetate

Receptor side effects2,3,4

Receptors Common side effects by stimulation of receptors
Oestrogenic Breast tenderness, enlargement, leg cramps, bloating, nausea, headache
Progestogenic PMS type symptoms, mood changes
Androgenic Oily skin, acne, hirsutism
Glucocorticoid Dosage and duration dependent: oedema, fluid retention, weight gain
Mineralcorticoid3 Oedema, weight gain, bloating and migraine

Why go low?

  • Both the International Menopause Society (IMS) and the British Menopause Society (BMS) recommended that women should be placed on the lowest effective doses5,7
  • Some benefits of going low.6,7
    • Provide adequate symptom relief
    • Higher rates of amenorrhoea and better tolerability profile
    • Less side effects and risk associated reduced progestogen required
    • Patients to be more compliant, realising the benefits of HRT
    • Can be used in new starters (if postmenopausal), ≥12 months since last period, long-term users and women who are considering weaning off

Dose comparison

Oestrogen Ultra Low Low Standard High
Conjugated equine
oestrogens (mg)
0.3 0.625 1.25
Micronized
17ß-oestradiol (mg)
0.5 1 2 4
Oestradiol
valerate (mg)
1 2
Transdermal
17ß-oestradiol (μg)
25 50 100

Table adapted from Maturitas, 40, Gambacciani M. Hormone replacement therapy: the benefits
in tailoring the regimen and dose. 195-201, Copyright (2001), with permission from Elsevier.

References
  1. Schindler AE. Maturitas 2003; 46(Suppl. 1): 7-16.
  2. Menopause matters, URL: https://www.menopausematters.co.uk/sideeffects.php.
  3. Jones EE. Am J Med 1995; 98(1A): 116S-9S.
  4. Panay N, et al. Human Reproduction Update 1997; 3( 2): 159-71.
  5. Baber RJ, et al. Climacteric 2016; 19(2): 109-50.
  6. Stevenson J, et al. Maturitas 2010; 67: 227-32.
  7. Panay N, et al. on behalf of the British Menopause Society (BMS) and Women’s Health Concern (WHC). Menopause International 2013; 19(2): 59-68.

HCP Disclaimer

This website is intended for healthcare professionals only.